Advances in the Study of Thyroid Hormones and Atrial Fibrillation
DOI:
https://doi.org/10.54097/rgg90n73Keywords:
Atrial Fibrillation, Thyroid Hormones, Treatment, ProgressAbstract
Atrial fibrillation (AF) is a common cardiac arrhythmia characterized by irregular, rapid and ineffective contractions of the atrial rhythm. The relationship between thyroid hormones and AF has been of interest because past studies have identified that thyroid hormones play an important role in the cardiovascular system and that there is a strong link between abnormal thyroid function and AF. Hyperthyroidism is often accompanied by symptoms of arrhythmia such as increased heart rate and arrhythmia, whereas hypothyroidism patients may exhibit abnormalities such as slowed heart rate and enlarged atria. Thyroid hormones are involved in the onset and development of AF through several pathways. First, thyroid hormone may affect the electrophysiological properties of cardiomyocytes, altering the excitability and repolarization process of atrial cells. Second, thyroid hormones may also affect the structure and function of the atria, leading to atrial enlargement and fibrosis, thereby increasing susceptibility to AF. In addition, thyroid hormones may alter the maintenance and regression of AF by affecting the autonomic regulation of the cardiovascular system. This suggests that thyroid hormones play a key role in the pathophysiologic mechanisms of AF. In recent years, an increasing number of studies have focused on the relationship between thyroid hormones and AF and have attempted to reveal their specific mechanisms of action. Some studies have suggested that modulation of thyroid function may be a new strategy for the treatment of atrial fibrillation. In this article, we present a review of the latest research progress on thyroid hormones and atrial fibrillation.
Downloads
References
Sussman MA. When the Thyroid Speaks, the Heart Listens. Circulation Research 2001;89:557–9. https://doi. org/10. 1161/ res.89.7.557.
Takawale A, Aguilar M, Bouchrit Y, Hiram R. Mechanisms and Management of Thyroid Disease and Atrial Fibrillation: Impact of Atrial Electrical Remodeling and Cardiac Fibrosis. Cells 2022; 11:4047. https://doi.org/10.3390/cells11244047.
Brent GA. Mechanisms of thyroid hormone action. J Clin Invest 2012;122:3035–43. https://doi.org/ 10. 1172/ JCI60047.
Klein I, Ojamaa K. Thyroid Hormone and the Cardiovascular System. New England Journal of Medicine 2001;344:501–9. https:// doi.org/10.1056/NEJM200102153440707.
Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res 2017;120:1501–17. https://doi.org/10. 1161/ CIRCRESAHA.117.309732.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. https://doi.org/ 10. 1093/ eurheartj/ ehaa612.
Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin Electrophysiol 2017; 3:425–35. https://doi.org/10.1016/j.jacep.2017.03.002.
Kim D, Smith TW. Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest 1984; 74:1481–8.
Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993;87:1435–41. https://doi.org/ 10. 1161/01.CIR.87.5.1435.
Page E, McCallister LP. Quantitative electron microscopic description of heart muscle cells: Application to normal, hypertrophied and thyroxin-stimulated hearts. The American Journal of Cardiology 1973;31:172–81. https://doi.org/ 10. 1016/ 0002-9149(73)91030-8.
Ross I, Omengan DB, Huang GN, Payumo AY. Thyroid hormone-dependent regulation of metabolism and heart regeneration. J Endocrinol 2022;252: R71–82. https://doi.org/ 10.1530/JOE-21-0335.
Kenessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 2006; 281:20666–72. https://doi.org/10.1074/jbc.M512671200.
Jia G, Sowers JR. Autoantibodies of β-Adrenergic and M2 Cholinergic Receptors: Atrial Fibrillation in Hyperthyroidism. Endocrine 2015; 49:301–3. https://doi.org/10.1007/s12020-015-0556-3.
Kato T, Iwasaki Y, Nattel S. Connexins and Atrial Fibrillation. Circulation 2012; 125:203–6. https:// doi. org/ 10.1161/ CIRCULATIONAHA. 111.075432.
Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009;35:288–94. https://doi.org/10.1055/s-0029-1222607.
Shah AJ, Liu X, Jadidi AS, Haïssaguerre M. Early management of atrial fibrillation: from imaging to drugs to ablation. Nat Rev Cardiol 2010;7:345–54. https://doi.org/ 10.1038/ nrcardio. 2010.49.
Naccarelli GV, Dell’Orfano JT, Wolbrette DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. The American Journal of Cardiology 2000;85:36–45. https://doi.org/10.1016/S0002-9149(00) 00905 -X.
Israeli A, Gal D, Younis A, Ehrenberg S, Rozner E, Turgeman Y, et al. Sex-Differences in Atrial Fibrillation Patients: Bias or Proper Management? Vasc Health Risk Manag 2022; 18:347–58. https://doi.org/10.2147/VHRM.S366285.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
